- Live webcast to be held on
The virtual event will feature presentations by Key Opinion Leader (“KOL”)
In preparation for the expected topline results for both its Phase 2b SOOTHE trial in RCC and Phase 2a BLUEPRINT trial in chronic pruritus associated with AD in
Event: BELLUS Health Virtual Analyst Event
Time: 12:00 –
The live webcast of the event may be accessed through the Events & Presentations page of BELLUS Health’s website, under the Investors & News section. The archived webcast and presentation will be available on the Company’s website after the event.
BLU-5937, a highly selective P2X3 antagonist, is in development for RCC, chronic pruritus and other hypersensitization-related disorders.
The P2X3 receptor, which is implicated in cough reflex hypersensitization, is a rational target for treating chronic cough, and it has been evaluated in multiple clinical trials with different P2X3 antagonists. The Company believes that its highly selective P2X3 antagonist has the potential to reduce coughing in patients with RCC, while limiting taste disturbance adverse events.
In addition to RCC and chronic pruritus, the mechanism of BLU-5937 may also have broad therapeutic applicability across other afferent hypersensitization-related disorders, enabling the Company to consider BLU-5937 as a potential treatment for a number of other indications. Consequently,
RCC is a cough lasting more than 8 weeks despite appropriate treatment for underlying condition(s). It is estimated that there are approximately 9 million patients in
Chronic pruritus associated with AD is an irritating sensation that leads to scratching and persists for longer than 6 weeks in AD patients. It is estimated that up to 10% of adults in
Certain statements contained in this news release, other than statements of fact that are independently verifiable at the date hereof, may constitute "forward-looking statements" within the meaning of Canadian securities legislation and regulations, the
FOR MORE INFORMATION:
Chief Financial Officer